Celgene, one of biopharma’s most aggressive and creative dealmakers, said Thursday it has forged a deep partnership with South San Francisco, CA-based Sutro Biopharma that could end up with an acquisition.
If it does, it would dramatically expand Celgene’s footprint into... Read more »
Here’s a quick rundown of recent news from Wisconsin’s technology and innovation community:
—Madison-based Deltanoid Pharmaceuticals announced top-line data from a Phase 2b clinical trial of its vitamin D-based drug, DP001, as a treatment for a hormonal imbalance that can occur... Read more »
Young Houston biotech companies will, by late next year, have a new partner in Johnson & Johnson.
The pharmaceutical giant said today that that it will house one of its J-Labs, formerly known as Janssen Labs, at the Texas Medical Center... Read more »
It’s notoriously difficult to develop drugs for pain, in part because the results from animal tests rarely hold up in human studies. Still, a new startup from Atlas Venture called Quartet Medicine will to try to navigate the minefield, buoyed by... Read more »
There’s been distressing Ebola-related news in recent days. The deadly virus continues to spread in West Africa, with more than 4,500 fatalities now reported, and efforts to halt its spread in the U.S. have been mired in controversy and confusion, forcing... Read more »
A biotech company developing an injectable drug to shrink the excess fat that forms “love handles” says it plans to raise more than $63 million through an IPO.
San Diego-based Neothetics, previously known as Lithera, has substantial backing from Domain Associates... Read more »
[Updated, 10/23/14, 4:41 pm ET] Rhythm Pharmaceuticals hinted that a strategic move was coming when a drug it’s been developing for diabetic gastroparesis cleared a key clinical hurdle earlier this year. That came to fruition today, because Actavis has... Read more »
Proteon Therapeutics is about to successfully pivot from a potential portfolio company of Novartis to a publicly traded entity—just not with the valuation it was hoping for.
Waltham, MA-based Proteon priced its IPO late Tuesday at $10 per share. The company... Read more »
Readers of this column who are of a certain age might remember Chrissie Hynde of the Pretenders in black eyeliner, dressed as a diner waitress singing, “I’m special, so special, and I gotta have some of your attention.”
Swap “money” for... Read more »